{"success":true,"data":{"pressRelease":{"id":"160543","rtpr_id":"nACSWk5xfa-20261005","ticker":"CEIN","exchange":"OTC","all_tickers":["CEIN"],"title":"Viking Global Technologies Announces Advancement of VKIN-300 Toward Completion of French Conformity Process","author":"ACCESSWIRE","published_at":"2026-10-05T12:30:01.300Z","article_body":"HOUSTON, TX / ACCESS Newswire (https://www.accessnewswire.com/) / October 5,\n2026 / Viking Global Technologies, Inc. (OTCQB:CEIN) (\"Viking\" or the\n\"Company\"), through its majority-owned subsidiary Viking Ozone Technology, LLC\n(\"Viking Ozone\"), today announced an important regulatory development\ninvolving its VKIN-300 medical and bio-hazardous waste treatment system.\n\nThe French government has formally incorporated NF X30-503-1:2024 into the\nregulatory framework governing applicable equipment used for the pretreatment\nby disinfection of infectious healthcare waste in France, replacing the prior\n2016 standard. The amendment was published in the Journal officiel de la\nRépublique française on September 24, 2026, with the amended provisions\ntaking effect September 25, 2026. This development completes the regulatory\nstep identified by the Company in November 2025 as necessary before formal\nconformity documentation for the VKIN-300 could be issued.\n(https://app.accessnewswire.com/imagelibrary/1c7490ba-5049-4df3-aa78-0592deb35a58/chatgpt-image-oct-1-2026-084227-am.png)\nJames Doris, President and Chief Executive Officer of Viking Global\nTechnologies, commented:\n\n\"This is an important regulatory development we have been waiting for. When we\nannounced LNE's acceptance of the VKIN-300 technical dossier last year, we\nexplained that the remaining regulatory framework in France first had to be\nupdated before the formal conformity process could be completed. France has\nnow taken that step.\"\n\n\"Considerable time, engineering expertise and capital have been invested in\ndeveloping the VKIN-300 and independently validating its performance. We\ndeliberately chose to pursue a rigorous French testing and regulatory process\nbecause we believe independent validation is essential when introducing a new\nwaste-treatment technology to hospitals, healthcare systems and\nwaste-management organizations. We are very pleased to have reached this stage\nand look forward to working with our partners through the remaining steps of\nthe process, including the upcoming Technical Committee review.\"\n\nA Differentiated Approach to Medical Waste Treatment\n\nThe VKIN-300 is a commercial-scale system designed to treat regulated medical,\ninfectious and bio-hazardous waste using ozone as an alternative to\nconventional medical-waste treatment approaches such as incineration and\nautoclaving.\n\nViking Ozone's technology combines a proprietary dynamic ozone-treatment\nprocess with an advanced microprocessor-based control and monitoring\narchitecture. The system is designed to manage and monitor critical treatment\nparameters, collect real-time operating data, maintain treatment records and\nprovide operators with visibility into system performance.\n\nThe VKIN-300 underwent extensive independent testing in France against the\nrequirements of NF X30-503-1:2024, including microbiological efficacy testing.\nThe Company has previously announced test results that the Company believes\ndemonstrated repeatable 6-log pathogen reduction, consistent with the\nmicrobiological efficacy requirements evaluated under the applicable standard.\n\nThe updated French regulatory framework also requires operators of applicable\nsystems to continuously record the disinfection parameters specified in the\napplicable conformity attestation. Viking believes this requirement aligns\nwell with the monitoring, control and data-recording capabilities engineered\ninto the VKIN-300.\n\nFrom Technical Validation to Final Regulatory Process\n\nViking previously announced that Laboratoire national de métrologie et\nd'essais (\"LNE\"), France's national laboratory for testing and metrology, had\ncompleted its acceptance review of the VKIN-300 technical dossier. At that\ntime, LNE notified the Company's agent that the application was complete and\ncompliant with the requirements of NF X30-503-1:2024.\n\nFormal issuance of the conformity documentation could not proceed, however,\nuntil France updated its existing regulatory framework to formally incorporate\nthe 2024 standard and implement the corresponding conformity-assessment\nframework. That regulatory update has now been completed.\n\nThe amended French regulation formally incorporates NF X30-503-1:2024 and sets\nout updated requirements governing the evaluation of applicable equipment and\nthe issuance of attestations of conformity. Viking Ozone's French distribution\npartner, BOX O3 France SARL (\"BOX O3\"), has advised Viking Ozone that LNE has\nindicated, based on the VKIN-300 technical documentation and test results\nsubmitted, that the system meets the technical requirements necessary to\nobtain an attestation of conformity under the new standard, and that LNE has\nscheduled a meeting of the applicable Technical Committee for October 14,\n2026. The Company has not independently received written confirmation from LNE\nof these matters, and issuance of that documentation remains subject to review\nby LNE's Technical Committee and completion of any of the LNE's remaining\nprocedures, and there can be no assurance as to whether or when it will be\nissued.\n\nSubject to the outcome of the Technical Committee review and completion of\nLNE's remaining procedures, BOX O3 currently anticipates that formal\nconformity documentation could be issued by the end of October 2026. The\nTechnical Committee may request additional information, require changes or\ntake additional time, and the timing and outcome of its review are outside the\nCompany's control. Accordingly, there can be no assurance that the conformity\ndocumentation will be issued within this time frame or at all.\n\nBuilding Toward Commercial Deployment\n\nViking believes completion of the French conformity process would represent an\nimportant step in the Company's broader strategy to commercialize the VKIN-300\ninternationally. Independent validation under a rigorous national regulatory\nframework can provide prospective customers and commercial partners with\nthird-party evidence regarding the system's treatment performance and\nregulatory readiness.\n\nThe Company and its partners are pursuing opportunities involving healthcare\ninstitutions, waste-management organizations and other potential customers and\npartners in multiple international markets. Viking believes successful\ncompletion of the French conformity process can provide an important technical\nand regulatory reference as it advances those commercialization efforts.\nReceipt of conformity documentation would not, by itself, result in sales or\nrevenue. As of the date of this release, the Company has not entered into any\nunconditional purchase orders or definitive commercial agreements for the\nVKIN-300. Any future commercial deployment will depend on, among other things,\ncustomer demand, financing, pricing, and the Company's ability to manufacture,\ninstall and support the system.\n\nThe Company intends to provide a further update upon receipt of the formal LNE\nconformity documentation.\n\nAbout Viking Ozone Technology, LLC\n\nViking Ozone Technology, LLC, a majority-owned subsidiary of Viking Global\nTechnologies, Inc., develops advanced ozone-based systems for the treatment of\nregulated medical, infectious and bio-hazardous waste. Viking Ozone's\ntechnology combines patented waste-treatment methodologies with advanced\nengineering, process-control and monitoring capabilities designed to provide\nan alternative to conventional medical waste-treatment methods.\n\nAbout Viking Global Technologies, Inc.\n\nViking Global Technologies, Inc. is a technology-focused company advancing\nproprietary solutions intended to address significant infrastructure,\nenvironmental and industrial challenges. Through its subsidiaries and\naffiliated businesses, the Company is developing and commercializing\ntechnologies including grid-protection solutions designed to improve\nelectric-grid resiliency and public safety and an ozone-based waste-treatment\nsystem, while evaluating additional strategic opportunities consistent with\nits long-term objectives. For more information, please visit\nwww.VikingGlobalTechnologies.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements. Forward-looking\nstatements include, among other things, statements regarding the anticipated\ntiming and outcome of LNE's Technical Committee review and the issuance of\nconformity documentation for the VKIN-300; the Company's business strategy and\ncommercialization efforts; the evaluation and deployment of its technologies;\nprospective customers and partners; international market opportunities; and\nfuture growth and strategic opportunities. Words such as \"anticipates,\"\n\"believes,\" \"expects,\" \"intends,\" \"could,\" \"may\" and similar expressions\nidentify forward-looking statements.\n\nForward-looking statements are based on current expectations, estimates,\nprojections and assumptions and are subject to risks and uncertainties that\ncould cause actual results to differ materially from those expressed or\nimplied by such statements. Factors that could cause actual results to differ\nmaterially include, among others: the possibility that LNE's Technical\nCommittee does not approve, delays or conditions issuance of conformity\ndocumentation for the VKIN-300; the Company's reliance on information provided\nby its distribution partner regarding the status of the LNE process; changes\nin French or other regulatory requirements; the Company's ability to obtain\nfinancing; the absence of binding customer commitments; and the other risks\ndescribed under \"Risk Factors\" in the Company's most recent Annual Report on\nForm 10-K and subsequent filings with the Securities and Exchange Commission.\nThere can be no assurance that the Company's technologies will achieve\ncommercial acceptance, that current or prospective evaluation or testing\nactivities will result in commercial deployments or revenues, or that the\nCompany will successfully execute its strategic objectives.\n\nReaders are cautioned not to place undue reliance on forward-looking\nstatements. Additional information regarding risks and uncertainties\napplicable to the Company is contained in the Company's filings with the\nSecurities and Exchange Commission. The Company undertakes no obligation to\nupdate forward-looking statements except as required by applicable law.\n\nInvestor Relations\n\nRenmark Financial Communications Inc.\nPreston Conable: pconable@renmarkfinancial.com\nTel: (416) 644-2020 or (212) 812-7680\nwww.renmarkfinancial.com\n\nSOURCE: Viking Global Technologies, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/oil-gas-and-energy/viking-global-technologies-announces-advancement-of-vkin-300-toward-completion-o-1232731)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSWk5xfa-20261005","title":"Viking Global Technologies Announces Advancement of VKIN-300 Toward Completion of French Conformity Process","author":"ACCESSWIRE","ticker":"CEIN","created":"2026-10-05T12:30:01.300Z","tickers":["CEIN"],"exchange":"OTC","article_body":"HOUSTON, TX / ACCESS Newswire (https://www.accessnewswire.com/) / October 5,\n2026 / Viking Global Technologies, Inc. (OTCQB:CEIN) (\"Viking\" or the\n\"Company\"), through its majority-owned subsidiary Viking Ozone Technology, LLC\n(\"Viking Ozone\"), today announced an important regulatory development\ninvolving its VKIN-300 medical and bio-hazardous waste treatment system.\n\nThe French government has formally incorporated NF X30-503-1:2024 into the\nregulatory framework governing applicable equipment used for the pretreatment\nby disinfection of infectious healthcare waste in France, replacing the prior\n2016 standard. The amendment was published in the Journal officiel de la\nRépublique française on September 24, 2026, with the amended provisions\ntaking effect September 25, 2026. This development completes the regulatory\nstep identified by the Company in November 2025 as necessary before formal\nconformity documentation for the VKIN-300 could be issued.\n(https://app.accessnewswire.com/imagelibrary/1c7490ba-5049-4df3-aa78-0592deb35a58/chatgpt-image-oct-1-2026-084227-am.png)\nJames Doris, President and Chief Executive Officer of Viking Global\nTechnologies, commented:\n\n\"This is an important regulatory development we have been waiting for. When we\nannounced LNE's acceptance of the VKIN-300 technical dossier last year, we\nexplained that the remaining regulatory framework in France first had to be\nupdated before the formal conformity process could be completed. France has\nnow taken that step.\"\n\n\"Considerable time, engineering expertise and capital have been invested in\ndeveloping the VKIN-300 and independently validating its performance. We\ndeliberately chose to pursue a rigorous French testing and regulatory process\nbecause we believe independent validation is essential when introducing a new\nwaste-treatment technology to hospitals, healthcare systems and\nwaste-management organizations. We are very pleased to have reached this stage\nand look forward to working with our partners through the remaining steps of\nthe process, including the upcoming Technical Committee review.\"\n\nA Differentiated Approach to Medical Waste Treatment\n\nThe VKIN-300 is a commercial-scale system designed to treat regulated medical,\ninfectious and bio-hazardous waste using ozone as an alternative to\nconventional medical-waste treatment approaches such as incineration and\nautoclaving.\n\nViking Ozone's technology combines a proprietary dynamic ozone-treatment\nprocess with an advanced microprocessor-based control and monitoring\narchitecture. The system is designed to manage and monitor critical treatment\nparameters, collect real-time operating data, maintain treatment records and\nprovide operators with visibility into system performance.\n\nThe VKIN-300 underwent extensive independent testing in France against the\nrequirements of NF X30-503-1:2024, including microbiological efficacy testing.\nThe Company has previously announced test results that the Company believes\ndemonstrated repeatable 6-log pathogen reduction, consistent with the\nmicrobiological efficacy requirements evaluated under the applicable standard.\n\nThe updated French regulatory framework also requires operators of applicable\nsystems to continuously record the disinfection parameters specified in the\napplicable conformity attestation. Viking believes this requirement aligns\nwell with the monitoring, control and data-recording capabilities engineered\ninto the VKIN-300.\n\nFrom Technical Validation to Final Regulatory Process\n\nViking previously announced that Laboratoire national de métrologie et\nd'essais (\"LNE\"), France's national laboratory for testing and metrology, had\ncompleted its acceptance review of the VKIN-300 technical dossier. At that\ntime, LNE notified the Company's agent that the application was complete and\ncompliant with the requirements of NF X30-503-1:2024.\n\nFormal issuance of the conformity documentation could not proceed, however,\nuntil France updated its existing regulatory framework to formally incorporate\nthe 2024 standard and implement the corresponding conformity-assessment\nframework. That regulatory update has now been completed.\n\nThe amended French regulation formally incorporates NF X30-503-1:2024 and sets\nout updated requirements governing the evaluation of applicable equipment and\nthe issuance of attestations of conformity. Viking Ozone's French distribution\npartner, BOX O3 France SARL (\"BOX O3\"), has advised Viking Ozone that LNE has\nindicated, based on the VKIN-300 technical documentation and test results\nsubmitted, that the system meets the technical requirements necessary to\nobtain an attestation of conformity under the new standard, and that LNE has\nscheduled a meeting of the applicable Technical Committee for October 14,\n2026. The Company has not independently received written confirmation from LNE\nof these matters, and issuance of that documentation remains subject to review\nby LNE's Technical Committee and completion of any of the LNE's remaining\nprocedures, and there can be no assurance as to whether or when it will be\nissued.\n\nSubject to the outcome of the Technical Committee review and completion of\nLNE's remaining procedures, BOX O3 currently anticipates that formal\nconformity documentation could be issued by the end of October 2026. The\nTechnical Committee may request additional information, require changes or\ntake additional time, and the timing and outcome of its review are outside the\nCompany's control. Accordingly, there can be no assurance that the conformity\ndocumentation will be issued within this time frame or at all.\n\nBuilding Toward Commercial Deployment\n\nViking believes completion of the French conformity process would represent an\nimportant step in the Company's broader strategy to commercialize the VKIN-300\ninternationally. Independent validation under a rigorous national regulatory\nframework can provide prospective customers and commercial partners with\nthird-party evidence regarding the system's treatment performance and\nregulatory readiness.\n\nThe Company and its partners are pursuing opportunities involving healthcare\ninstitutions, waste-management organizations and other potential customers and\npartners in multiple international markets. Viking believes successful\ncompletion of the French conformity process can provide an important technical\nand regulatory reference as it advances those commercialization efforts.\nReceipt of conformity documentation would not, by itself, result in sales or\nrevenue. As of the date of this release, the Company has not entered into any\nunconditional purchase orders or definitive commercial agreements for the\nVKIN-300. Any future commercial deployment will depend on, among other things,\ncustomer demand, financing, pricing, and the Company's ability to manufacture,\ninstall and support the system.\n\nThe Company intends to provide a further update upon receipt of the formal LNE\nconformity documentation.\n\nAbout Viking Ozone Technology, LLC\n\nViking Ozone Technology, LLC, a majority-owned subsidiary of Viking Global\nTechnologies, Inc., develops advanced ozone-based systems for the treatment of\nregulated medical, infectious and bio-hazardous waste. Viking Ozone's\ntechnology combines patented waste-treatment methodologies with advanced\nengineering, process-control and monitoring capabilities designed to provide\nan alternative to conventional medical waste-treatment methods.\n\nAbout Viking Global Technologies, Inc.\n\nViking Global Technologies, Inc. is a technology-focused company advancing\nproprietary solutions intended to address significant infrastructure,\nenvironmental and industrial challenges. Through its subsidiaries and\naffiliated businesses, the Company is developing and commercializing\ntechnologies including grid-protection solutions designed to improve\nelectric-grid resiliency and public safety and an ozone-based waste-treatment\nsystem, while evaluating additional strategic opportunities consistent with\nits long-term objectives. For more information, please visit\nwww.VikingGlobalTechnologies.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements. Forward-looking\nstatements include, among other things, statements regarding the anticipated\ntiming and outcome of LNE's Technical Committee review and the issuance of\nconformity documentation for the VKIN-300; the Company's business strategy and\ncommercialization efforts; the evaluation and deployment of its technologies;\nprospective customers and partners; international market opportunities; and\nfuture growth and strategic opportunities. Words such as \"anticipates,\"\n\"believes,\" \"expects,\" \"intends,\" \"could,\" \"may\" and similar expressions\nidentify forward-looking statements.\n\nForward-looking statements are based on current expectations, estimates,\nprojections and assumptions and are subject to risks and uncertainties that\ncould cause actual results to differ materially from those expressed or\nimplied by such statements. Factors that could cause actual results to differ\nmaterially include, among others: the possibility that LNE's Technical\nCommittee does not approve, delays or conditions issuance of conformity\ndocumentation for the VKIN-300; the Company's reliance on information provided\nby its distribution partner regarding the status of the LNE process; changes\nin French or other regulatory requirements; the Company's ability to obtain\nfinancing; the absence of binding customer commitments; and the other risks\ndescribed under \"Risk Factors\" in the Company's most recent Annual Report on\nForm 10-K and subsequent filings with the Securities and Exchange Commission.\nThere can be no assurance that the Company's technologies will achieve\ncommercial acceptance, that current or prospective evaluation or testing\nactivities will result in commercial deployments or revenues, or that the\nCompany will successfully execute its strategic objectives.\n\nReaders are cautioned not to place undue reliance on forward-looking\nstatements. Additional information regarding risks and uncertainties\napplicable to the Company is contained in the Company's filings with the\nSecurities and Exchange Commission. The Company undertakes no obligation to\nupdate forward-looking statements except as required by applicable law.\n\nInvestor Relations\n\nRenmark Financial Communications Inc.\nPreston Conable: pconable@renmarkfinancial.com\nTel: (416) 644-2020 or (212) 812-7680\nwww.renmarkfinancial.com\n\nSOURCE: Viking Global Technologies, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/oil-gas-and-energy/viking-global-technologies-announces-advancement-of-vkin-300-toward-completion-o-1232731)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-05T12:30:01.507063028Z","server_sent_at_ms":1791203401507},"received_at":"2026-10-05T12:30:01.560Z","source_url":"https://www.accessnewswire.com/newsroom/en/oil-gas-and-energy/viking-global-technologies-announces-advancement-of-vkin-300-toward-completion-o-1232731"},"analysis":{"id":"149105","press_release_id":"160543","analysis_json":{"industry":{"label":"Commercial Services & Supplies","sector":"Industrials"},"redFlags":["Company has not independently received written confirmation from LNE — relying on distributor BOX O3's account","Technical Committee review outcome and timing outside company control; conformity issuance not assured","No binding purchase orders or definitive commercial agreements; conformity alone yields no revenue","Pre-revenue micro-cap flagging financing ability as a risk factor"],"eventType":"regulatory","narrative":"Viking Global Technologies announced that France formally incorporated the NF X30-503-1:2024 standard into its regulatory framework for disinfecting infectious healthcare waste, effective September 25, 2026.\n\nThis completes the regulatory prerequisite Viking identified in November 2025 before LNE could issue formal conformity documentation for the VKIN-300 ozone-based medical waste treatment system; a Technical Committee review is scheduled for October 14, 2026, with BOX O3 anticipating possible issuance by end of October.\n\nViking has not independently received written confirmation from LNE, and even if conformity is granted it would not generate revenue — the company discloses it has no unconditional purchase orders or definitive commercial agreements for the VKIN-300.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Regulatory gate cleared for VKIN-300 in France, but LNE Technical Committee review on Oct 14 is the real binary catalyst — and conformity still translates to zero revenue today."},"keyFigures":{"drugName":"VKIN-300","customDimensions":{"standard":"NF X30-503-1:2024","pathogen_reduction":"6-log","regulation_effective":"September 25, 2026","technical_committee_meeting":"October 14, 2026","expected_conformity_issuance":"end of October 2026"}},"quotedText":"Receipt of conformity documentation would not, by itself, result in sales or revenue. As of the date of this release, the Company has not entered into any unconditional purchase orders or definitive commercial agreements for the VKIN-300.","namedEntities":{"people":[{"name":"James Doris","role":"President and CEO"}],"products":["VKIN-300"],"companies":[{"name":"Viking Global Technologies, Inc.","ticker":"CEIN","relationship":"filer"},{"name":"Viking Ozone Technology, LLC","relationship":"majority-owned subsidiary"},{"name":"BOX O3 France SARL","relationship":"French distribution partner"},{"name":"Laboratoire national de métrologie et d'essais (LNE)","relationship":"French testing/metrology laboratory"},{"name":"Renmark Financial Communications Inc.","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"France formally incorporated the NF X30-503-1:2024 standard, completing a prerequisite step toward LNE conformity for the VKIN-300. But conformity documentation is not yet issued, depends on an Oct 14 Technical Committee review outside the company's control, and would not by itself generate revenue; the company has no binding purchase orders."},"tickerRelevance":{"others":[],"primary":"CEIN"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap OTCQB","eventGravity":"interim regulatory milestone, no revenue impact","issuerAuthored":true,"speculativePreRevenue":true}},"event_type":"regulatory","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Viking Global Technologies announced that France formally incorporated the NF X30-503-1:2024 standard into its regulatory framework for disinfecting infectious healthcare waste, effective September 25, 2026.\n\nThis completes the regulatory prerequisite Viking identified in November 2025 before LNE could issue formal conformity documentation for the VKIN-300 ozone-based medical waste treatment system; a Technical Committee review is scheduled for October 14, 2026, with BOX O3 anticipating possible issuance by end of October.\n\nViking has not independently received written confirmation from LNE, and even if conformity is granted it would not generate revenue — the company discloses it has no unconditional purchase orders or definitive commercial agreements for the VKIN-300.","key_figures":{"drugName":"VKIN-300","customDimensions":{"standard":"NF X30-503-1:2024","pathogen_reduction":"6-log","regulation_effective":"September 25, 2026","technical_committee_meeting":"October 14, 2026","expected_conformity_issuance":"end of October 2026"}},"named_entities":{"people":[{"name":"James Doris","role":"President and CEO"}],"products":["VKIN-300"],"companies":[{"name":"Viking Global Technologies, Inc.","ticker":"CEIN","relationship":"filer"},{"name":"Viking Ozone Technology, LLC","relationship":"majority-owned subsidiary"},{"name":"BOX O3 France SARL","relationship":"French distribution partner"},{"name":"Laboratoire national de métrologie et d'essais (LNE)","relationship":"French testing/metrology laboratory"},{"name":"Renmark Financial Communications Inc.","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T12:30:20.592Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap OTCQB","eventGravity":"interim regulatory milestone, no revenue impact","issuerAuthored":true,"speculativePreRevenue":true}},"durationMs":6623,"modelName":"glm-5.3-flashx"}}